The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV. It also recommends the shot during ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

The Centers for Disease Control and Prevention's vaccine advisory committee wrapped up the first day of its meeting since Health and Human Services Secretary Robert F. Kennedy Jr. dismissed the entire ...

The RSV hospitalization rate among seniors in the most recent season was higher than it’s been for at least six years, according to data from the CDC. There were also high levels of flu, and ...

GSK’s vaccine Arexvy and Pfizer’s vaccine Abrysvo were available last season, according to the CDC. On May 31, a third shot developed by Moderna, mResvia, was also approved.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.